# Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

> **NCT07390123** · PHASE3 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 370 (estimated)

## Conditions studied

- IgA Nephropathy (IgAN)

## Interventions

- **DRUG:** HSK39297
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07390123
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-12
- **Final completion:** 2028-07
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07390123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07390123, "Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT07390123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*